Aro Biotherapeutics and Ionis Enter Licensing and Collaboration Agreement Focused on Cell-Specific Delivery of Antisense Oligonucleotides

Aro Biotherapeutics Company announces it has entered a licensing and collaboration agreement with Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, through which Ionis will use Aros CENTYRIN technology to develop targeted cell- and tissue- specific delivery of antisense oligonucleotides (ASOs).